Survey Reveals Biotech Professionals' Attitude Toward New Business Models
A recent, free report, reveals biotech professionals' evaluations of potential business model alternatives for the future.
The following table shows the results of respondents' answers to the question: Given that some of the more traditional avenues to drug development could be facing problems, from the list below please indicate any change in your company’s stance or relative interest in using each drug development model/partner. As you will see from the following responses, choices varied greatly.
Source: Industry Standard Research, 2009.
You can view the full report here.
For more information on biotech, please see:
More Data Points:
How Digital Technology and Remote Assessment Strategies Can Aid Clinical Trial Research
July 24th 2020While there's been hopeful news on treatments and vaccines, sponsors should plan to discuss necessary strategies and contingencies at the outset of new studies or re-opening of halted studies during the COVID-19 pandemic.
